Likewise, combined therapy of RMC-4550 plus MRTX849 resulted in significantly greater anti-tumor efficacy in 4 out of 6 KRAS G12C in vivo models, compared to monotherapy (93). The gene discussed is KRAS; the disease is neoplasm.